Whalegun
Home

Ultragenyx Pharmaceutical RARE paid Mehlman Consulting $60K for lobbying in Q2 2026 · Health Issues, Budget

Trade details

Type
Lobbying report
Amount
$60,000
Quarter
Q2 2026
Stock
Ultragenyx Pharmaceutical RARE
Client
Ultragenyx Pharmaceutical
Reported
26/07/20

Up 0.0% from last quarter

What else happened in Ultragenyx Pharmaceutical around then

Filed or reported within 30 days of the trade day · 05/31~07/30

Ultragenyx Pharmaceutical's other lobbying reports